9 results about "Leukemia inhibitory factor" patented technology

The invention belongs to the technical field of biology, and discloses a serum-free culture medium and application thereof in obtaining nerve cells through embryo fibroblast transdifferentiation. The serum-free culture medium consists of a basic culture medium, a protein additive and cell culture auxiliary components, the protein additive consists of transferrin, a leukemia inhibition factor and a basic fibroblast growth factor; the final concentration of the transferrin is 5 ng / mL-30 ng / mL, the final concentration of the leukemia inhibition factor is 50 ng / mL-150 ng / mL, and the final concentration of the basic fibroblast growth factor is 10 ng / mL-25 ng / mL. The serum-free culture medium can promote the conversion speed of transdifferentiation of fibroblasts into nerve cells, can significantly improve the transdifferentiation efficiency, and can improve the cell survival rate of transdifferentiation of mouse embryo fibroblasts into nerve cells.

The invention relates to the technical field of cell culture, in particular to a method for induced culture of embryonic stem cells. The method comprises the following steps: resuscitating cryopreserved Balb / c mouse embryonic stem cells, culturing with a culture solution A containing leukemia inhibition factors, and continuously culturing with a culture solution B containing Activin A after passage; sequentially culturing in an HM culture medium added with specific cell factors, and cooperatively using a cell induction matrix prepared from various components such as hyaluronic acid, 3-aminophenylboronic acid, mono-ammonium glycyrrhizinate and the like. Through the synergistic effect of each culture step and each component in the cell induction matrix, the liver microenvironment is simulated, the cell growth factors are slowly released, and meanwhile, the anti-oxidation characteristic of quercetin is exerted, so that the induced differentiation efficiency of the embryonic stem cells is effectively improved.

The invention provides a composition, a cell culture medium and application of the cell culture medium in establishment of trophoblast stem cells in bovine hatching blastocysts, and belongs to the technical field of cell engineering. The invention provides a composition. The composition comprises activin A, CHIR99021 and a recombinant human leukemia inhibition factor. After the composition is adopted to culture hatched blastocysts, bovine trophoblast stem cells are obtained in vitro, trophoblast cell specific markers are highly expressed in mRNA and protein levels, and the bovine trophoblast stem cells can be stably cultured in vitro for a long time. The composition not only can further enrich the culture system of the bovine trophoblast stem cells, but also can expand understanding of the difference of signal pathways causing the blastocysts in different stages of the cattle.

The invention relates to the technical field of information, and particularly provides an automatic sorting method for germline stem cells of plectropomus leopardus, which comprises the following steps: selecting healthy plectropomus leopardus as a raw material, anesthetizing with eugenol, taking gonads, cleaning the gonads with a 1 * PBS buffer solution containing antibiotics and an antifungal agent under an aseptic condition, and drying to obtain germline stem cells of plectropomus leopardus; removing surface blood vessels and coating membranes, and cutting into tissue blocks; the method comprises the following steps: re-suspending gonad cells by using a 1 * PBS buffer solution, adding a predetermined volume of suspension into the 1 * PBS buffer solution mixed with trehalose lipid and glycine betaine in a predetermined ratio, incubating, centrifuging, discarding supernatant, and pre-treating the cells to obtain pre-treated cells; putting the separated germline stem cells into a basal culture medium, adding serum, mercaptoethanol, a GlutaMAX additive, a basic fibroblast growth factor, a leukemia inhibition factor and a glial cell-derived neurotrophic factor, and culturing.

The present invention belongs to the technical field of stem cells. Provided are a culture medium for induced hypoblast stem cells and the use thereof. Provided is a culture medium for induced hypoblast stem cells. The components of the culture medium comprise platelet-derived growth factor AA, a leukemia inhibitory factor, fibroblast growth factor 4, GSK-3α / β inhibitor CHIR99021, TGF-β type I receptor inhibitor A83-01, and bone morphogenetic protein 4. The culture medium for induced hypoblast stem cells can accurately regulate the activity of key signaling pathways such as NODAL, BMP, WNT, FGF, and JAK / STAT in the process of somatic cell reprogramming, and ensure that the properties of hypoblast stem cells are maintained in the process of somatic cell reprogramming to support the self-renewal and hypoblast lineage induction of somatic cells in the reprogramming process, thereby realizing the fate transition of somatic cells to hypoblast stem cells.

Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram / ml; ascorbic acid at a concentration range of about 400-600 microgram / ml, bFGF at a concentration range of about 50-200 ng / ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg / ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units / ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The present application relates to the technical field of cell biology, and specifically discloses a goat embryonic stem cell culture system, a method for establishing a cell line and application, wherein the goat embryonic stem cell culture system is based on mTeSR TM Plus as a basic culture solution, and 20ng / mL-25ng / mL leukemia inhibitory factor, 1M-1.5M PD0325901, 4M-5M IWR-1, 45g / mL-50g / mL Vc, 15ng / mL-20ng / mL activin A, 1-1.2M CGP77675 and 1.5-2M GO6983 are added. The present application can obtain cell clones with clear edges by culturing the goat embryonic stem cell culture system, and the cell clones can be stably passaged and have the potential to differentiate into three germ layers.